The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
The Danish government is to remove the rules that currently prohibit the purchase of medicines from countries outside the European Union (EU) in a move that has not been welcomed by pharma. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). 30 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
President Biden has said the USA will commit at least $500 million to support African countries in battling the ongoing mpox outbreak in Central and Eastern Africa. 25 September 2024
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
The Foundation for Economic and Industrial Research and Greek pharma trade group the Hellenic Association of Pharmaceutical Companies have presented two studies reflecting the industry’s importance. 23 September 2024
Basilea Pharmaceutica announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) has awarded Basilea an Other Transaction Agreement (OTA), under OTA number 75A50124C00033. 20 September 2024
Novo Nordisk is under increasing pressure over the cost of its blockbuster drugs in the USA, as chief executive Lars Fruergaard Jørgensen prepares to testify before a powerful Senate committee. 18 September 2024
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
The budget on October 30 is an opportunity to end short-termism, cut waste, and attract long-term investment to the country’s economy with a sector-targeted R&D tax relief policy, according to the UK BioIndustry Association (BIA). 3 September 2024
The Danish Pharmaceutical Industry Association, Lif, has given its verdict on the government financial bill setting out new priorities in health in 2025. 2 September 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
Companies marketing expensive drugs in the USA will no longer just be able to tell TV viewers just the good news about their products’ therapeutic potential along with a mention of side-effects. 9 May 2019
Trade group Medicines Australia said today that it welcomes the announcement from the Australian Labor Party (ALP) to reform the Research and Development (R&D) Tax Incentive if elected on May 18. 8 May 2019
Right-wing think tank The Institute for Policy Innovation (IPI) has commented on the ongoing Congressional debate over “Medicare for all” proposals, condemning the idea as imposing: “socialist price controls on Medicare's prescription drugs.” 8 May 2019
Top Russian pharmaceutical manufacturers and global drugmakers, operating in the local market have called on the government to provide additional guarantees for the safety of their business in the country and to create conditions for their comfortable development in the local market. 7 May 2019
Amid multiple Congressional investigations into drug pricing in the USA, and a febrile political atmosphere around the role of the state in insurance and pricing negotiations, the nonpartisan Congressional Budget Office (CBO) released a report into so-called “Medicare for all” on Thursday. 2 May 2019
The UK government has unveiled improvements to its Accelerated Access Collaborative (AAC) with the promise of making it the new umbrella organization for UK health innovation. 2 May 2019
The US House Committee on Rules held the first hearing on Medicare for all legislation this week, and, while the subject matter was familiar, the hearing itself was unusual, according to Stephanie Kennan of McGuireWoods Consulting. 2 May 2019
The fact that Greece has regained its financial independence after an eight-year bailout program does not mean that the crisis is over in the country’s pharma market, according to Olympios Papadimitriou. 29 April 2019
The European Parliament today voted overwhelmingly with 572 Members of Parliament in favor to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver. 17 April 2019
The Economist Intelligence Unit (EIU) has predicted that Russia’s pharma market will grow by nearly 5% in 2019 from 2018, in US dollar terms. 11 April 2019
The Russian government plans to support the development of the domestic production of active pharmaceutical ingredients (APIs) by the provision of subsidies for their exports, according to Denis Manturov, an official spokesman of the Russian Minister of Industry and Trade, reports The Pharma Letter’s local correspondent. 9 April 2019
The president of Greek industry association the Hellenic Association of Pharmaceutical Companies (SFEE), painted an alarming picture on the current and future state of Greek healthcare at the group’s general assembly meeting. 8 April 2019
A major fillip has been provided by the Indian government for new drugs approved for use in the EU, UK, Australia, Japan and the USA. Newly-minted clinical trial rules in India state drugs that have been approved in these countries no longer require trials in India, reports The Pharma Letter’s India correspondent. 5 April 2019
The year-long US-China tension demands a fairer Chinese market access for global companies, and it might benefit China’s drug innovation, said speakers at the annual China Healthcare Investment Conference (CHIC) event held in Shanghai on March 27. 4 April 2019
Major US insurer Cigna has moved to cap insulin prices for customers, together with its new acquisition Express Scripts, a pharmacy benefits manager (PBM). 4 April 2019
Medicines Australia welcomes the announcement of A$331 million ($236 million) for the listings of innovative medicines on the country’s Prescription Benefits Scheme (PBS) in today’s 2019/20 Federal Budget. 2 April 2019
The Maryland House of Delegates this week voted 98 to 40 to create a Prescription Drug Affordability Board, an independent body with the authority to evaluate high-cost prescription drugs and set rates for state and local governments to pay. 29 March 2019